NanoViricides is trading 6.19% higher at $1.63 after rising following a 9.17% regular-session decline on September 22, 2026; the cause remains unclear. - No September 22 company announcement or explicit after-hours catalyst was identified. - The latest company update, dated September 15, concerned the planned NV-387 Phase II Ebola trial in the Democratic Republic of Congo; it did not explain the move. - The Nasdaq Composite was up 0.62%, offering modestly supportive broader sentiment.